Since the first report on the development of a selective inhibitor of LIMK activity by Bristol-Myers-Squibb in 2006, only one such molecule has reached clinical trials for treating glaucoma (Ross-Macdonald et al., 2008). Here, LIMK1 is linked to glaucoma.